273 related articles for article (PubMed ID: 29556979)
1. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
[TBL] [Abstract][Full Text] [Related]
2. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
4. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; MacGowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz de Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez LM; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
J Antimicrob Chemother; 2021 Jul; 76(8):2172-2181. PubMed ID: 33993273
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia.
Huang YC; Lin YT; Wang FD
Int J Antimicrob Agents; 2018 Jan; 51(1):47-51. PubMed ID: 28668676
[TBL] [Abstract][Full Text] [Related]
6. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.
Scheetz MH; Bolon MK; Scarsi KK; Fotis MA; Postelnick MJ
J Infect; 2006 Feb; 52(2):105-10. PubMed ID: 15904961
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
Yan LZ; Herrington JD
J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
[TBL] [Abstract][Full Text] [Related]
10. Oral beta-lactam step down in bacteremic E. coli urinary tract infections.
Saad S; Mina N; Lee C; Afra K
BMC Infect Dis; 2020 Oct; 20(1):785. PubMed ID: 33087051
[TBL] [Abstract][Full Text] [Related]
11. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
[TBL] [Abstract][Full Text] [Related]
12. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
[TBL] [Abstract][Full Text] [Related]
13. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Tan SH; Teng CB; Ng TM; Lye DC
Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
[TBL] [Abstract][Full Text] [Related]
15. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.
Hu Y; Li L; Li W; Xu H; He P; Yan X; Dai H
Int J Antimicrob Agents; 2013 Dec; 42(6):492-6. PubMed ID: 24139926
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli.
Al-Hasan MN; Wilson JW; Lahr BD; Thomsen KM; Eckel-Passow JE; Vetter EA; Tleyjeh IM; Baddour LM
Antimicrob Agents Chemother; 2009 Apr; 53(4):1386-94. PubMed ID: 19164144
[TBL] [Abstract][Full Text] [Related]
18. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
[TBL] [Abstract][Full Text] [Related]
19. Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis.
Onorato L; Macera M; Calò F; Cirillo P; Di Caprio G; Coppola N
Int J Antimicrob Agents; 2022 Mar; 59(3):106512. PubMed ID: 34971728
[TBL] [Abstract][Full Text] [Related]
20. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
